Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 14,300 Shares of Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 14,300 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $110.16, for a total value of $1,575,288.00. Following the completion of the sale, the insider directly owned 59,634 shares in the company, valued at approximately $6,569,281.44. The trade was a 19.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Deborah Ann Miller also recently made the following trade(s):

• On Wednesday, January 21st, Deborah Ann Miller sold 700 shares of Nuvalent stock. The shares were sold at an average price of $109.84, for a total transaction of $76,888.00.
• On Tuesday, January 6th, Deborah Ann Miller sold 2,589 shares of Nuvalent stock. The shares were sold at an average price of $97.16, for a total transaction of $251,547.24.
• On Monday, January 5th, Deborah Ann Miller sold 4,363 shares of Nuvalent stock. The shares were sold at an average price of $97.32, for a total value of $424,607.16.
• On Monday, November 17th, Deborah Ann Miller sold 24,200 shares of Nuvalent stock. The shares were sold at an average price of $105.50, for a total transaction of $2,553,100.00.
• On Thursday, October 30th, Deborah Ann Miller sold 21,800 shares of Nuvalent stock. The shares were sold at an average price of $103.16, for a total value of $2,248,888.00.

Nuvalent Price Performance

Shares of NASDAQ NUVL traded down $5.55 during mid-day trading on Friday, reaching $106.44. The company’s stock had a trading volume of 448,397 shares, compared to its average volume of 619,348. The stock has a fifty day moving average of $104.92 and a two-hundred day moving average of $90.87. Nuvalent, Inc. has a 52 week low of $55.53 and a 52 week high of $113.01. The firm has a market capitalization of $7.74 billion, a PE ratio of -20.01 and a beta of 1.32.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings data on Thursday, October 30th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.31). During the same period last year, the company earned ($1.28) earnings per share. Analysts anticipate that Nuvalent, Inc. will post -3.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NUVL. GAMMA Investing LLC lifted its position in shares of Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after acquiring an additional 108 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in Nuvalent in the 3rd quarter valued at about $38,000. Eastern Bank purchased a new position in Nuvalent during the 3rd quarter valued at about $52,000. Persistent Asset Partners Ltd purchased a new stake in shares of Nuvalent in the second quarter valued at about $88,000. Finally, Farther Finance Advisors LLC grew its position in shares of Nuvalent by 9,230.8% in the second quarter. Farther Finance Advisors LLC now owns 1,213 shares of the company’s stock valued at $93,000 after purchasing an additional 1,200 shares during the last quarter. Hedge funds and other institutional investors own 97.26% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on NUVL shares. Cantor Fitzgerald assumed coverage on shares of Nuvalent in a research report on Wednesday, October 15th. They set an “overweight” rating and a $135.00 target price on the stock. HC Wainwright upped their price objective on Nuvalent from $130.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. Leerink Partners upped their price target on Nuvalent from $140.00 to $149.00 and gave the stock an “outperform” rating in a report on Monday, November 17th. Barclays set a $152.00 price objective on shares of Nuvalent in a report on Monday, November 17th. Finally, Guggenheim increased their price objective on Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Fifteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $138.33.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.